{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-081562","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.138814+00:00","generated_at":"2026-06-04T05:17:29.652652+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Interim CFO Drexler resigns; Garner appointed PFO/PAO, will depart May 15, 2024","bullets":["Susan L. Drexler resigned as Interim CFO, PFO and PAO effective March 25, 2024; remains consultant via Danforth Advisors.","Charles Garner appointed as principal financial officer and principal accounting officer effective March 25, 2024.","Garner's employment ends May 15, 2024; he will receive 12 months base salary severance if not terminated for cause or he quits without good reason before then.","Garner previously SVP Finance since Oct 2023, former CFO of Lung Therapeutics (acquired by Aileron).","No permanent CFO replacement announced; leadership transition in finance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-081562","json":"https://secwatch.observer/filing/0001193125-24-081562.json","markdown":"https://secwatch.observer/filing/0001193125-24-081562.md","text":"https://secwatch.observer/filing/0001193125-24-081562.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/0001193125-24-081562-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/d800276d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:17:29.652652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3accafab46","claim":"Charles Garner was appointed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..","evidence_excerpt":"the Board of Directors of the Company appointed Charles Garner to serve as the Company’s principal financial officer and principal accounting officer, effective as of March 25, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/0001193125-24-081562-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer and principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"7e0772ab00","claim":"Susan L. Drexler resigned as Interim Chief Financial Officer, principal financial officer and principal accounting officer at Rein Therapeutics, Inc..","evidence_excerpt":"On March 25, 2024, Susan L. Drexler, Interim Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc. (the “Company”), notified the Company of her resignation, effective as of March 25, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/0001193125-24-081562-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim Chief Financial Officer, principal financial officer and principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"cc81a639d7","claim":"Charles Garner departed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..","evidence_excerpt":"Separately, the Company and Mr. Garner have agreed that his employment with the Company will end effective as of May 15, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/0001193125-24-081562-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"agreed that his employment will end"},{"label":"Role","value":"principal financial officer and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}